Literature DB >> 26041802

Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis.

Natalie F Baruch1, Ellen H O'Donnell2, Bonnie I Glanz1, Ralph H B Benedict3, Alexander J Musallam1, Brian C Healy4, David Rintell1, Tanuja Chitnis5.   

Abstract

BACKGROUND: Little is known about long-term cognitive and patient-reported outcomes of pediatric-onset multiple sclerosis (POMS).
OBJECTIVE: The objective of this paper is to compare cognitive and patient-reported outcomes in adults with POMS vs. adult-onset MS (AOMS).
METHODS: We compared standardized patient-reported measures MSQOL54, MFIS, CES-D and SDMT in adult patients with MS onset prior to and after age 18, using data gathered in the Comprehensive Longitudinal Investigations in MS at Brigham and Women's Hospital (CLIMB) study.
RESULTS: Fifty-one POMS and 550 AOMS patients were compared. SDMT scores were significantly lower in POMS after adjusting for age (-7.57 (-11.72, -3.43; p < 0.001), but not after adjusting for disease duration. Estimated group difference demonstrated lower normative z scores in POMS vs. AOMS in unadjusted analysis (-0.74 (95% CI: -1.18, -0.30; p = 0.0009) and after adjusting for disease duration (-0.60; 95%CI: -1.05, -0.15; p = 0.0097). Findings were unchanged in a subset of POMS diagnosed prior to age 18. In unadjusted and adjusted analyses, no significant differences were observed in health-related quality-of-life, fatigue, depression or social support between POMS and AOMS.
CONCLUSIONS: Younger age of onset was associated with more impairment in information-processing speed in adults with POMS compared to AOMS, and remained significant when controlling for disease duration in age-normed analysis. The two groups were similar in terms of patient-reported outcomes, suggesting similar qualitative experiences of MS.
© The Author(s), 2015.

Entities:  

Keywords:  Multiple sclerosis; cognition; outcomes; pediatric; quality of life

Mesh:

Year:  2015        PMID: 26041802     DOI: 10.1177/1352458515588781

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  8 in total

1.  Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.

Authors:  Damiano Baroncini; Angelo Ghezzi; Clara Guaschino; Lucia Moiola; Massimo Filippi; Antonio Ianniello; Carlo Pozzilli; Roberta Lanzillo; Vincenzo Brescia-Morra; Monica Margoni; Paolo Gallo; Graziella Callari; Luigi Grimaldi; Giacomo Lus; Massimiliano Calabrese; Marta Simone; Girolama Alessandra Marfia; Sarah Rasia; Daniela Cargnelutti; Giancarlo Comi; Mauro Zaffaroni
Journal:  Neurol Sci       Date:  2022-07-04       Impact factor: 3.307

2.  No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab.

Authors:  Monica Margoni; Francesca Rinaldi; Alice Riccardi; Silvia Franciotta; Paola Perini; Paolo Gallo
Journal:  J Neurol       Date:  2019-09-27       Impact factor: 4.849

Review 3.  Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis.

Authors:  Marisa McGinley; Ian T Rossman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 4.  Pediatric Multiple Sclerosis and Cognition: A Review of Clinical, Neuropsychologic, and Neuroradiologic Features.

Authors:  Ozgul Ekmekci
Journal:  Behav Neurol       Date:  2017-12-25       Impact factor: 3.342

Review 5.  Pediatric multiple sclerosis: current perspectives on health behaviors.

Authors:  Elizabeth Morghen Sikes; Robert W Motl; Jayne M Ness
Journal:  Pediatric Health Med Ther       Date:  2018-03-06

6.  Progress in the Management of Paediatric-Onset Multiple Sclerosis.

Authors:  Aphra Luchesa Smith; Christina Benetou; Hayley Bullock; Adam Kuczynski; Sarah Rudebeck; Katie Hanson; Sarah Crichton; Kshitij Mankad; Ata Siddiqui; Susan Byrne; Ming Lim; Cheryl Hemingway
Journal:  Children (Basel)       Date:  2020-11-09

7.  Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

Authors:  Omar A Abdel-Mannan; Celeste Manchoon; Thomas Rossor; Justine-Clair Southin; Carmen Tur; Wallace Brownlee; Susan Byrne; Manali Chitre; Alasdair Coles; Rob Forsyth; Rachel Kneen; Kshitij Mankad; Dipak Ram; Siobhan West; Sukhvir Wright; Evangeline Wassmer; Ming Lim; Olga Ciccarelli; Cheryl Hemingway; Yael Hacohen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-21

Review 8.  Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities.

Authors:  Monica Margoni; Francesca Rinaldi; Paola Perini; Paolo Gallo
Journal:  Front Neurol       Date:  2021-05-17       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.